Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Pasithea Therapeutics Corp ( (KTTA) ) is now available.
On June 23, 2025, Pasithea Therapeutics Corp received a notice from Nasdaq indicating non-compliance with the $1.00 minimum bid price requirement, which could lead to delisting if not rectified. The company has 180 days to regain compliance, with options to extend this period or appeal if necessary, but the notice does not affect its business operations or SEC reporting requirements.
More about Pasithea Therapeutics Corp
Pasithea Therapeutics Corp operates in the biotechnology industry, focusing on developing innovative medical treatments. The company is engaged in the research and development of therapies for neurological and psychiatric disorders.
Average Trading Volume: 6,273,769
Technical Sentiment Signal: Sell
Current Market Cap: $5.39M
See more insights into KTTA stock on TipRanks’ Stock Analysis page.